Ladenburg analyst Michael Higgins maintained a Buy rating on Savara Inc (SVRA) today and set a price target of $21. The company’s shares opened today at $10.99.
Higgins observed:
“We believe IMPALA is likely to succeed given GM-CSF’s central role in aPAP, prior trial results and Molgradex’s confirmed low systemic exposure and safety profile.”
According to TipRanks.com, Higgins has currently no stars on a ranking scale of 0-5 stars, with an average return of -4.9% and a 33.3% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Paratek Pharmaceuticals, and Zynerba Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Savara Inc with a $20 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.06 and a one-year low of $6.21. Currently, Savara Inc has an average volume of 213.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
